Avalo Therapeutics, Inc. Common Stock (AVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AVTX trades at $16.31 with a market cap of $849.46M and a P/E ratio of -2.79. AVTX moved +0.15% today. Year to date, AVTX is +1.62%; over the trailing twelve months it is +297.32%. Its 52-week range spans $3.39 to $24.27. Analyst consensus is strong buy with an average price target of $46.78. Rallies surfaces AVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Avalo Reports 42.9% HiSCR75 Response, Raises $431.3M in Offering: Avalo Therapeutics reported Phase 2 LOTUS results showing 42.2% and 42.9% HiSCR75 improvements at Week 16 versus 25.6% placebo (p=0.018 and p=0.015). The company raised $431.3 million in an offering and held $82 million in cash and short-term investments at March 31, 2026, funding operations into 2029.
| Metric | Value |
|---|---|
| Price | $16.31 |
| Market Cap | $849.46M |
| P/E Ratio | -2.79 |
| EPS | $-5.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.27 |
| 52-Week Low | $3.39 |
| Volume | 26 |
| Avg Volume | 0 |
| Revenue (TTM) | $59.00K |
| Net Income | $-78.26M |
| Gross Margin | 0.00% |
9 analysts cover AVTX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $46.78.